02 May Braeburn and Camurus Announce Positive Top-line Results from CAM2038 Safety Study
Posted at 19:39h in Press Release
Princeton, New Jersey and Lund, Sweden — 2 May 2017 — Braeburn Pharmaceuticals and Camurus (NASDAQ STO: CAMX) today announced positive top-line results from a long-term Phase 3 trial supporting the safety and efficacy of CAM2038 (weekly and monthly buprenorphine depots) in patients with moderate-to-severe opioid use disorder.“The positive results...